Frederick B. Stehman

Indiana University Hospital — United States

Medicine · Health Sciences

44h-index9.3kcitations149works0.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(65), Endometrial and Cervical Cancer Treatments(54), Cervical Cancer and HPV Research(34), Colorectal and Anal Carcinomas(14), Intraperitoneal and Appendiceal Malignancies(11)

Publications149 total

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

eScholarship (California Digital Library)·2017Open Access

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience

98 cited

Gynecologic Oncology·2017· 98 citedOpen Access

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

658 cited

The Lancet·2017· 658 citedOpen Access

Disease Extent at Secondary Cytoreductive Surgery is Predictive of Progression-free and Overall Survival in Advanced Stage Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group study

PMC·2016

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis

eScholarship (California Digital Library)·2016Open Access

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

13 cited

Gynecologic Oncology·2016· 13 citedOpen Access

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis

49 cited

Gynecologic Oncology·2016· 49 citedOpen Access

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

1 cited

Gynecologic Oncology·2016· 1 citedOpen Access

Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy

3 cited

PMC·2015· 3 cited

182 cited

Journal of Clinical Oncology·2015· 182 citedOpen Access

Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation

2014

Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation

118 cited

Gynecologic Oncology·2014· 118 citedOpen Access

Impact of age on tolerance of chemoradiation and survival for patients with local regionally advanced cervical cancer: A pooled analysis of Gynecologic Oncology Group (GOG) phase III trials

Gynecologic Oncology·2014

Wound morbidity of groin node dissection performed after radiation for vulvar cancer

Gynecologic Oncology·2013

Gynecologic oncology group strategies to improve timeliness of publication

5 cited

Clinical Trials·2013· 5 cited

Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study